<DOC>
	<DOCNO>NCT00951535</DOCNO>
	<brief_summary>This prospective , phase II non-randomised control clinical study . Dose escalation implement use 1.8 Gy increment baseline 75.6 Gy . Patients ' RT prescription may escalate max 81 Gy dose volume constraint adhere . All patient treat use participate institution 's standard rectal preparation protocol , bladder-filling protocol appropriate immobilisation device ( ) . Cone beam CT on-treatment imaging recommend study . However , use individual institutional image equipment technique permit . Acute GU/GI toxicity assess weekly treatment . GU/GI toxicity also assess 2 month post RT , 8 month post RT 6 monthly thereafter year nine line participate institution 's standard routine follow-up ( FU ) thereafter .</brief_summary>
	<brief_title>A Prospective Phase II Dose Escalation Study Using IMRT High Risk N0 M0 Prostate Cancer . ICORG 08-17</brief_title>
	<detailed_description>Primary Objective : To determine dose escalate IMRT high risk localise prostate cancer provide PSA relapse free survival similar report Memorial Sloan Kettering ( Alicikus et al 2011 Secondary Objectives : - Overall survival disease-free survival rate . - To evaluate significance publish prognostic/ stratification factor UCSF-CAPRA score ass application data study . - To achieve maximum dose escalation ( 81Gy ) . This assessed percentage patient receive dose level category ( dose increment 1.8 Gy 75.6 Gy max 81 Gy ) . - The incidence severity acute late GU GI toxicity describe , correlate DVH parameter</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patients undergoing radical course RT highrisk disease ( define accord National Comprehensive Cancer Network Practice Guidelines Oncology v.1 one NCCN high risk criterion &gt; equal T3 , &gt; equal Gleason 8 , PSA &gt; 20ng/ml ) 2 . Only patient require neoadjuvant / adjuvant hormonal therapy include study 3 . Absence distant metastasis demonstrate history physical examination , FBC , screen profile include liver function test , PSA bone scan 4 . All patient must MRI/CT prostate pelvis investigate nodal status precise Tstage . This MRI/CT scan must perform prior commencement hormonal therapy . Suspicious node need histologically proven benign patient include study ) . M0 stag . 5 . No previous surgery urinary condition except TURP TRUS 6 . KPS &gt; equal 60 7 . Age &gt; 18 year 8 . Provision write informed consent line ICHGCP guideline 1 . Previous RT pelvic region 2 . The patient nodal involvement decide electively treat pelvic lymph node 3 . The patient bilateral orchidectomy 4 . The patient previously receive full course hormonal treatment prostate cancer 5 . The patient malignancy within last 5 year ( nonmelanoma skin cancer permit ) 6 . Evidence significant clinical disorder laboratory find make undesirable patient participate trial felt research/ medical team patient may able comply protocol 7 . Patients prostatectomy 8 . The presence hip prosthesis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>